(Press-News.org) Clinical trial shows promising results for PanChol, a single-dose oral vaccine aimed at the up to 4 million annual cholera cases worldwide
A team of scientists and physicians at Mass General Brigham has developed a single-dose oral cholera vaccine and tested it in a phase 1 clinical trial, with results published in The Lancet Infectious Diseases.
“The devastating cholera outbreak in Haiti in 2010 triggered my desire to create a new oral live-attenuated cholera vaccine,” said co–senior author Matthew K. Waldor, MD, PhD, a principal investigator in the Division of Infectious Diseases in the Mass General Brigham Department of Medicine. “Existing vaccines made from inactivated bacteria require multiple doses and are not that efficacious, particularly in young children, the population most at risk of dying from cholera. Our research on the cholera pathogen suggested ways to make improved vaccines. We hope our vaccine will be deployed where it is most needed to save lives—in places where cholera is endemic and during outbreaks.”
Up to 4 million cholera cases and 143,000 related deaths occur annually, with approximately 1.3 billion people at risk of disease, which is caused by ingestion of Vibrio cholerae bacteria in tainted water or food. These bacteria produce toxins that cause severe vomiting and diarrhea.
Waldor and his colleagues derived their new vaccine, called PanChol, from a weakened version of the Vibrio cholerae strain that is currently responsible for most global cholera cases. The group added certain characteristics to make the live vaccine safe and prevent it from regaining the ability to produce toxins and cause disease.
In the 57-participant phase 1 trial, individuals received increasing doses of PanChol to identify the most effective dose. Based on these findings, additional participants were randomly assigned to receive either one oral dose of PanChol or one oral dose of placebo.
As the most important goal of a phase 1 trial is to ensure safety, Waldor and his collaborators were pleased to observe that adverse events were typically mild and transient. Whole-genome sequencing of PanChol isolated from vaccinated participants’ stool samples confirmed the vaccine’s genomic stability, which is needed to ensure its safety. PanChol shedding, a marker for vaccine replication in the intestine, was detectable across vaccine doses, and 100% of people who were vaccinated mounted strong immune responses against Vibrio cholerae antigens two weeks after vaccination.
"This work represents a significant step forward in our efforts to combat a devastating disease and shows what can be accomplished at MGB given the depth of our scientific talent,” said co–senior author Lindsey Baden, MD, vice president of clinical research at Mass General Brigham. “This achievement is a testament to the collaborative spirit among research scientists and clinical trial experts at Mass General Brigham who share a commitment to improving the lives of patients both here and globally.”
An important next step in PanChol development is to test the vaccine in places where cholera is endemic. To that end, an additional phase I trial of PanChol will be begin in Lusaka, Zambia sometime in early 2026.
Authorship: In addition to Waldor, Mass General Brigham authors include Deborah R Leitner (co-first author), Stephen R Walsh (co-first author), Masataka Suzuki, Michaël Desjardins, Alisse Hannaford, Amy C Sherman, Hannah Levine, Lena Carr, Elliot Hammerness, Akina Osaki, Emily Sullivan, Bryan Wang, George I Balazs, Jun Bai Park Chang, Damien M Slater, Nirajan Puri, Carole J Kuehl, Jason B Harris, Steven Piantadosi, and Lindsey R Baden (co-last author). An additional author includes Wilbur H Chen.
Disclosures: Waldor is an inventor on a patent related to PanChol. Additional author disclosures can be found in the paper.
Funding: This study is supported by a Wellcome Trust grant (218443/Z/19/Z) to Waldor and Baden. Waldor is supported by US National Institutes of Health (NIH) grant RO1AI042347-29 and the Howard Hughes Medical Institute. Baden is supported by US National Institute of Allergy and Infectious Diseases (NIAID) grant 5-UM1-AI-069412-19 and the Harvard Clinical and Translational Science Center (1UL1TR002541-01). Hannaford is supported by NIH T32 grant AI007061. Sherman is supported by NIH grant 1K23AI185318–01A1. Harris is supported by NIAID grant R01AI179917.
Paper cited: Leitner DR et al. “Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial” Lancet Infectious Diseases DOI: 10.1016/S1473-3099(25)00682-6
###
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
END
Overview
Anthracene—a hydrocarbon known for its strong luminescence and high photo-reactivity—has long been considered one of the most iconic and widely studied organic molecules. Its [4+4] photocycloaddition reaction, first reported in 1867, has underpinned the development of countless photo-functional materials, including actuators, adhesives, and chromic systems.
Despite being a textbook reaction, the structural changes during this photoreaction occur in an extremely short time window (10⁻⁸–10⁻⁶ s), placing the process beyond direct experimental observation for more than a century. Consequently, controlling and visualizing ...
People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, say experts at UCL and the University of Cambridge.
In research published today in Obesity Reviews, the team, led by Dr Marie Spreckley from the University of Cambridge, found a lack of robust evidence surrounding nutritional advice and support and the impact this has on factors such as calorie intake, body composition, protein adequacy, and patient experiences.
Weight ...
Dogs fed on premium, meat-rich pet food can have a bigger dietary carbon pawprint than their owners, according to the largest study into dog food’s climate impact.
In particular, wet, raw and meat-rich products are associated with substantially higher greenhouse gas emissions than dry dog food.
Overall, the production of ingredients used in UK dog food is estimated to contribute around one per cent of the country’s total greenhouse gas emissions.
The findings highlight the need for greater transparency and better labelling of dog food ingredients to help consumers make informed choices, as pet ownership continues to rise, experts say.
Scientists ...
Millions of Britons could be ready to swap imported fish for home‑caught favourites like sardines, sprats and anchovies – according to a new study from the University of East Anglia (UEA).
A new report reveals that more than 40 per cent of consumers are willing to experiment with fish they’ve never tried before.
The study suggests the UK is overlooking a major opportunity to improve national health and bolster local economies by embracing its own rich stocks of small, nutritious fish.
The study was led by researchers at UEA’s Centre for Social and Economic Research ...
An estimated 1.6 million adults in England, Wales and Scotland used drugs such as Wegovy and Mounjaro to help lose weight between early 2024 and early 2025, according to a new study by UCL (University College London) researchers.
The research, published in BMC Medicine and funded by Cancer Research UK, found that an additional 3.3 million people said they would be interested in using weight loss drugs over the next year.
The team looked at data from 5,260 people who were representative of the general population ...
American College of Cardiology President Christopher M. Kramer, MD, FACC, issued the following statement on the release of new Dietary Guidelines for Americans by the U.S. Department of Health and Human Services (HHS) and U.S. Department of Agriculture.
“The ACC acknowledges and appreciates the release of new federal nutrition guidance and remains committed to helping clinicians and patients use it to support heart health,” said ACC President Christopher M. Kramer, MD, FACC.
“We welcome the inclusion of several important science-based recommendations, ...
MILWAUKEE, WI and CAMBRIDGE, MA – January 7, 2026 – The American Society of Gene & Cell Therapy (ASGCT), the leading professional organization for the advancement of cell and gene therapies (CGTs), and the Orphan Therapeutics Accelerator (OTXL), a non-profit biotech focused on completing development and enabling access to stalled rare disease treatments, today announced a partnership to establish CGTxchange, a jointly owned entity that will serve as a clearinghouse and marketplace for deprioritized CGTs.
The new joint venture will address a growing and urgent challenge facing the CGT field: policy and economic shifts in ...
Two new studies published in Anaesthesia (the journal of the Association of Anaesthetists) analysing pain and other factors connected with day surgery in the UK show that around 1 in 8 patients having day-case surgery end up not going home and instead are admitted to hospital for various complications. Furthermore, one in 14 go on to develop chronic pain at the operative site after the procedure.
The studies are by Dr Martha Belete, Torbay and South Devon NHS Foundation Trust, Torbay, Devon, UK and Dr Adam Brayne, University Hospitals Plymouth NHS Trust, ...
Violent crime has fallen to historic lows in Chicago, although gun violence continues to plague neighborhoods with concentrated poverty. A 2023 study of five major cities showed that more than 55% of shootings occurred in just 9% of total census tracts, and that small increases in things like poverty, unemployment, or limited access to health care are associated with large increases in firearm violence.
Yet not every neighborhood that struggles with these challenges also has high rates of violence. ...
In a surprising twist amid rising climate concerns, new research shows that scorching soil temperatures during extreme heatwaves do not necessarily boost the uptake of toxic elements like arsenic in rice crops. This finding, from a real world experiment during China's record breaking 2022 heatwaves, challenges fears that global warming will poison staple foods.
"Our study reveals that soil warming alone, decoupled from air temperature rises, does not inevitably ramp up arsenic or heavy metal accumulation in rice grains," said Sha Zhang, ...
